deltatrials
Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05046314

A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma

The Efficacy and Safety of TK216 in Subjects With Relapsed or Refractory Ewing's Sarcoma：a Phase II Clinical Trial in China

Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Conditions Sarcoma, Ewing
Interventions TK216+Vincristin
Updated 15 times since 2021 Last updated: Jan 12, 2026 Started: Mar 12, 2024 Primary completion: Sep 13, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05046314, this PHASE2 trial focuses on Sarcoma, Ewing and remains actively recruiting participants. Sponsored by Shanghai Pharmaceuticals Holding Co., Ltd, it has been updated 15 times since 2024, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Oct 2021 – ~Mar 2022 · 5 months · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Mar 2023 · 4 months · monthly snapshot~Mar 2023 – ~Jun 2023 · 3 months · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Sep 2023 · 2 months · monthly snapshot~Sep 2023 – ~Dec 2023 · 3 months · monthly snapshot~Dec 2023 – ~May 2024 · 5 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Feb 2026 · 13 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

15 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE2

  2. Jan 2025 — Feb 2026 [monthly]

    Recruiting PHASE2

  3. Sep 2024 — Jan 2025 [monthly]

    Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  5. May 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

▶ Show 10 earlier versions

  1. Dec 2023 — May 2024 [monthly]

    Not Yet Recruiting PHASE2

  2. Sep 2023 — Dec 2023 [monthly]

    Not Yet Recruiting PHASE2

  3. Jul 2023 — Sep 2023 [monthly]

    Not Yet Recruiting PHASE2

  4. Jun 2023 — Jul 2023 [monthly]

    Not Yet Recruiting PHASE2

  5. Mar 2023 — Jun 2023 [monthly]

    Not Yet Recruiting PHASE2

  6. Nov 2022 — Mar 2023 [monthly]

    Not Yet Recruiting PHASE2

  7. Sep 2022 — Nov 2022 [monthly]

    Not Yet Recruiting PHASE2

  8. Apr 2022 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE2

  9. Mar 2022 — Apr 2022 [monthly]

    Not Yet Recruiting PHASE2

  10. Oct 2021 — Mar 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Shanghai Pharmaceuticals Holding Co., Ltd
Data source: Shanghai Pharmaceuticals Holding Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations